The novel hybrid agonist HyNDA‐1 targets the D3R‐nAChR heteromeric complex in dopaminergic neurons

@article{Matera2019TheNH,
  title={The novel hybrid agonist HyNDA‐1 targets the D3R‐nAChR heteromeric complex in dopaminergic neurons},
  author={Carlo Matera and Federica Bono and Silvia Pelucchi and Ginetta Collo and Leonardo Bontempi and Cecilia Gotti and Michele Zoli and Marco De Amici and Cristina Missale and Chiara Fiorentini and Clelia Dallanoce},
  journal={Biochemical Pharmacology},
  year={2019},
  volume={163},
  pages={154–168}
}

Figures and Tables from this paper

Structural Plasticity of Dopaminergic Neurons Requires the Activation of the D3R-nAChR Heteromer and the PI3K-ERK1/2/Akt-Induced Expression of c-Fos and p70S6K Signaling Pathway

TLDR
The D3R-nAChR heteromer and its ability to trigger the PI3K-ERK1/2/Akt signaling pathways may represent a novel target for preserving dopaminergic neurons healthy and for conferring neuronal protection against injuries.

Dopamine D3 Receptor Heteromerization: Implications for Neuroplasticity and Neuroprotection

TLDR
The functional and pharmacological characteristics of D3R are summarized, including the capability to form active heteromers as pharmacological targets for specific neurodegenerative disorders and a possible key etiologic effector for DA-related pathologies, such as Parkinson’s disease (PD).

Novel Analgesic Agents Obtained by Molecular Hybridization of Orthosteric and Allosteric Ligands

TLDR
The functional characterization of the new ligands in vitro and the assessment of their efficacy as analgesic agents and tolerability in mice are reported, providing new insights for the development and optimization of novel muscarinic hybrid compounds for the management of pain.

Dopamine Receptor Subtypes, Physiology and Pharmacology: New Ligands and Concepts in Schizophrenia

TLDR
The review summarizes the recent advances in the field, addressing the relevance of emerging new targets in schizophrenia in particular in relation to the dopamine – glutamate NMDA systems interactions.

Integration and Spatial Organization of Signaling by G Protein-Coupled Receptor Homo- and Heterodimers

TLDR
Evidence is summarized that supports the hypothesis that the formation of GPCRs higher order oligomers provides the structural basis for organizing distinct cell compartments along the plasma membrane where confined increases in second messengers may be perceived and discriminated, fostering new ideas about the physiological role played by receptor homo- and hetero-oligomerization in cell biology.

References

SHOWING 1-10 OF 70 REFERENCES

Bifunctional compounds targeting both D2 and non-α7 nACh receptors: design, synthesis and pharmacological characterization.

In vitro pharmacological profile of YM‐43611, a novel D2‐like receptor antagonist with high affinity and selectivity for dopamine D3 and D4 receptors

TLDR
The results indicate that YM‐43611 is a novel D2‐like receptor antagonist with high potency and selectivity for both D3 and D4 receptors, and is expected to be valuable in exploration of the physiological role of D 3 and D 4 receptors.

Novel 3-Pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors.

TLDR
A novel series of 3-pyridyl ether compounds which possess subnanomolar affinity for brain nA cholinergic channel modulators and differentially activate subtypes of neuronal nAChRs are reported.

Investigation of novel ropinirole analogues: synthesis, pharmacological evaluation and computational analysis of dopamine D2 receptor functionalized congeners and homobivalent ligands

TLDR
The development of novel functionalized congeners of ropinirole toward the design of pharmacological tools to probe structural requirements at the dopamine D2 receptor and potential novel treatment for Parkinson's disease is reported.

Synthesis and pharmacological evaluation of dual acting ligands targeting the adenosine A2A and dopamine D2 receptors for the potential treatment of Parkinson's disease.

TLDR
The integrated dual acting ligands showed promising results in preliminary blood-brain barrier permeability tests, whereas the classical heterobivalent ligands are potentially more suited as pharmacological tools.

Structure-guided development of heterodimer-selective GPCR ligands

TLDR
The structure-guided design, chemical synthesis and biological investigations of bivalent ligands for dopamine D2 receptor/neurotensin NTS1 receptor (D2R/NTS1R) heterodimers are reported, which show binding affinity in the picomolar range for cells coexpressing both GPCRs and unprecedented selectivity compared with cells that only express D2Rs.

Dopamine D3 receptor‐preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons

TLDR
The results suggest that D3 dopamine receptor‐preferring agonists, PPX and ROP, exert neurotrophic effects on cultured DA neurons by modulating the production of endogenous GDNF and BDNF, which may participate in their neuroprotection.
...